Venclexta Side Effects May Increase Risk Of Death In Multiple Myeloma Patients: FDA
The FDA warns that clinical trials indicate Venclexta can increase the risk of death when given off-label to patients for the treatment of multiple myeloma.
The FDA warns that clinical trials indicate Venclexta can increase the risk of death when given off-label to patients for the treatment of multiple myeloma.